2018-09-21| Trials & Approvals

AJOVY™, Teva’s new migraine drug gets USFDA approval

by Rajaneesh K. Gopinath
Share To

Just four months after Aimovig™ (erenumab), codeveloped by Amgen and Novartis, the migraine community rejoices in the approval of yet another injectable migraine drug.
By Rajaneesh K Gopinath

Migraine is a neurological disorder caused by the release of inflammatory substances in the brain that manifests as severe headaches, accompanied by nausea and vomiting. One of the proteins that causes migraine is the calcitonin gene-related peptide (CGRP). On September 14th, Teva Pharmaceutical Industries Ltd announced the approval of their injectable drug, AJOVY™ (fremanezumab-vfrm) by the United States Food and Drug Administration (USFDA). The drug is a humanized monoclonal antibody that binds to CGRP, effectively obstructing the ligand from binding to its receptor and blocking its activity in the process. On the contrary, Aimovig targets CGRP receptor, rather than the ligand. AJOVY™ now becomes the second anti-CGRP treatment after Aimovig to be approved by the FDA for prevention of migraine in adults.

AJOVY™ is approved only for subcutaneous use and two recommended dosing options are currently available for patients; a 225 mg (monthly), or 675 mg every 3 months (quarterly), which is administered as three consecutive doses of 225 mg each. The efficacy of the drug was evaluated as a preventive treatment of episodic or chronic migraine in two multicenter, randomized Phase III, placebo-controlled clinical trials that enrolled patients with migraine. 662 patients received AJOVY™ 225 mg (monthly) for 12 weeks (with or without a loading dose of 675 mg), and 663 patients received AJOVY™ 675 mg (quarterly) for 12 weeks. In these trials, patients experienced a reduction in monthly migraine days. The most common adverse reactions were injection site reactions.

Headquartered in Israel, Teva has production and research facilities all around the globe. Their phase III trials of AJOVY™ were conducted in early 2017 and the application for FDA approval was submitted last October. Currently, AJOVY™ is priced at $575 per monthly dose and $1,725 per quarterly dose.




© All rights reserved. Collaborate with us:
Related Post
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
APAC Leading the Industry in Adoptive Cell Therapy – Trials, Economic Growth, and Pioneering Companies
Taiwan’s Biotech and Pharma Delegation: Innovations Take Center Stage at BIO 2024
Breaking Ground in Alzheimer’s with 10 Cutting-Edge Treatments Paving the Way in 2024
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
Scroll to Top